Matinas BioPharma Holdings, Inc

(NYSE MKT:MTNB)

Latest On Matinas BioPharma Holdings, Inc (MTNB):

Date/Time Type Description Signal Details
2023-05-11 08:13 ESTNewsMatinas BioPharma Holdings, Inc. 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-11 08:13 ESTNewsMatinas BioPharma Holdings, Inc. (MTNB) Q1 2023 Earnings Call TranscriptN/A
2023-05-10 18:23 ESTNewsMatinas Biopharma GAAP EPS of -$0.03 in-line, revenue of $1.1M beats by $0.8MN/A
2023-05-10 05:10 ESTNewsMatinas Biopharma Q1 2023 Earnings PreviewN/A
2023-04-20 00:45 ESTNewsMatinas jumps 25% to hit four-month high on data for anti-fungal agentN/A
2023-03-16 05:19 ESTNewsMatinas Biopharma GAAP EPS of -$0.10 beats by $0.01N/A
2023-03-16 05:19 ESTNewsMatinas BioPharma Holdings, Inc. (MTNB) Q4 2022 Earnings Call TranscriptN/A
2023-01-31 18:04 ESTNewsGilead abandons oral version of COVID drug remdesivir with Matinas BiopharmaN/A
2023-01-28 12:01 ESTNewsStocks To Watch: Investors Gear Up For Fed Meeting, Earnings Rush And Jobs ReportN/A
2023-01-12 12:15 ESTNewsMatinas stock rises on team up with National Resilience for drug delivery technologyN/A
2022-11-03 12:29 ESTNewsMatinas BioPharma Holdings, Inc. (MTNB) Q3 2022 Earnings Call TranscriptN/A
2022-11-02 20:27 ESTNewsMatinas Biopharma GAAP EPS of -$0.03 in-line, revenue of $1.1M beats by $0.25MN/A
2022-11-02 04:21 ESTNewsMatinas Biopharma Q3 2022 Earnings PreviewN/A
2022-10-21 09:48 ESTNewsMatinas BioPharma says mid-stage study for meningitis therapy met main goalN/A
2022-09-21 11:32 ESTNewsEric J. Ende is the new Chairman of the Board of Matinas BiopharmaN/A
2022-08-12 05:22 ESTNewsMatinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerry Jabbour on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-11 12:40 ESTNewsMatinas Biopharma GAAP EPS of -$0.03 in-line, revenue of $1.06M beats by $1MN/A
2022-07-25 16:13 ESTNewsMatinas stock rises as MAT2203 gets EMA panel nod for orphan drug statusN/A
2022-06-12 01:06 ESTNewsMatinas BioPharma (MTNB) Investor Presentation - SlideshowN/A
2022-05-13 21:52 ESTNewsMatinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerome Jabbour on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-12 20:46 ESTNewsMatinas Biopharma GAAP EPS of -$0.03N/A
2022-05-12 20:45 ESTNewsMatinas BioPharma (MTNB) CEO, Jerome Jabbour on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-12 02:15 ESTNewsMatinas Biopharma Q1 2022 Earnings PreviewN/A
2022-03-08 16:57 ESTNewsMatinas Biopharma GAAP EPS of -$0.03 beats by $0.01N/A
2022-03-08 16:56 ESTNewsMatinas BioPharma Holdings, Inc. (MTNB) CEO Jerome Jabbour On Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-07 23:04 ESTNewsMatinas Biopharma Q4 2021 Earnings PreviewN/A
2022-01-25 15:52 ESTNewsMatinas BioPharma falls 17% amid pipeline, business updates for 2022N/A
2021-12-16 10:28 ESTNewsMatinas Bio gains 7% on DSMB approval to proceed with final cohort of MAT2203 trialN/A
2021-11-08 15:28 ESTNewsMatinas Biopharma EPS misses by $0.01, misses on revenueN/A
2021-11-08 15:27 ESTNewsMatinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerome Jabbour on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-06 05:20 ESTNewsMatinas Biopharma Q3 2021 Earnings PreviewN/A
2021-10-21 10:41 ESTNewsMatinas Biopharma initiates dosing in early-stage MAT2501 trialN/A
2021-09-23 07:40 ESTNewsMatinas BioPharma gains 16% on Gilead remdesivir dataN/A
2021-09-22 01:05 ESTNewsMatinas BioPharma up 22% on phase 2 data on meningitis candidateN/A
2021-09-22 01:01 ESTNewsMatinas BioPharma hot streak continues as shares up another 15% todayN/A
2021-09-22 01:01 ESTNewsMatinas: Positive Trial Data Has This Stock On The MoveN/A
2021-08-16 21:36 ESTNewsMatinas BioPharma issued U.S. patent protecting MAT2203N/A
2021-08-11 04:46 ESTNewsMatinas BioPharma Holdings, Inc. (MTNB) CEO Jerome Jabbour on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-10 07:54 ESTNewsMatinas Biopharma EPS beats by $0.01N/A
2021-03-31 05:09 ESTNewsMatinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerome Jabbour on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-29 14:37 ESTNewsMatinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerry Jabbour on Q4 2020 Results - Earnings Call TranscriptN/A
2021-02-03 12:18 ESTAnalyst RatingThe Analyst Target Price has decreased from $3.75 to $3.42.Neutral
2021-02-01 16:58 ESTNewsMatinas Bio's Lypdiso achieved significantly higher EPA levels and lower triglycerides compared to VascepaN/A
2021-01-06 23:16 ESTNewsMatinas: Learning From Amarin's MistakesN/A
2021-01-06 16:14 ESTFinancialsCompany financials have been released.Neutral
2021-01-05 12:20 ESTAnalyst RatingThe Analyst Target Price has increased from $3.38 to $3.75.Buy
2021-01-04 12:25 ESTNewsMatinas Biopharma's MAT9001 gets conditional FDA nod for LYPDISO brand nameN/A
2020-12-08 08:39 ESTNewsMatinas Bio to evaluate oral formulations of Gilead’s antiviral remdesivir, shares up 15%N/A
2020-12-03 03:31 ESTNewsMatinas BioPharma Holdings (MTNB) Investor Presentation - SlideshowN/A
2020-11-26 20:54 ESTFinancialsCompany financials have been released.Neutral

About Matinas BioPharma Holdings, Inc (MTNB):

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.

MTNB Quotes by TradingView

See Advanced Chart

General

  • Name Matinas BioPharma Holdings, Inc
  • Symbol MTNB
  • Type Common Stock
  • Exchange NYSE MKT
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 21
  • Fiscal Year EndDecember
  • IPO Date2014-08-18
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.matinasbiopharma.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 2371.18
  • Price/Book (Most Recent Quarter) 3.76
  • Enterprise Value Revenue 1947.47
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.03
  • Operating Margin -24473%
  • Return on Assets -25%
  • Return on Equity -41%
  • Revenue 95833
  • Earnings Per Share -$0.13
  • Revenue Per Share $0
  • Gross Profit -11144736
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 235.58 million
  • EBITDA -15456706
  • PE Ratio -1.02
  • Analyst Target Price $3.42
  • Book Value Per Share $0.32
View More

Share Statistics

  • Shares Outstanding 199.64 million
  • Shares Float 180.03 million
  • % Held by Insiders 771%
  • % Held by Institutions 23.63%
  • Shares Short 15.52 million
  • Shares Short Prior Month 15.43 million
  • Short Ratio 2.17
  • Short % of Float 8%
  • Short % of Shares Outstanding 8%
View More

Technicals

  • Beta 2.82
  • 52 Week High $2.22
  • 52 Week Low $0.49
  • 50 Day Moving Average 1.29
  • 200 Day Moving Average 1.07
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Matinas BioPharma Holdings, Inc (MTNB) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Matinas BioPharma Holdings, Inc (MTNB) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-06$N/A-$0.03-$0.039.91%
2020-06-302020-08-10$N/A-$0.03-$0.035.36%
2020-03-312020-05-11$N/A-$0.03-$0.036.25%
2019-12-312020-03-09$N/A-$0.04-$0.03-20.12%
2019-09-302019-11-13$N/A-$0.03-$0.037.69%
2019-06-302019-08-13$89812-$0.03-$0.0414.29%
2019-03-312019-04-01$N/A-$0.03-$0.030%
2018-12-312018-12-31$119750-$0.03-$0.030%
2018-09-302018-11-09$-89813-$0.03-$0.0425%
2018-06-302018-08-09$89813-$0.04-$0.040%
2018-03-312018-05-09$29937-$0.05-$0.04-25%
2017-12-312018-03-16$45000-$0.03-$0.0425%
2017-09-302017-11-14$45000-$0.04-$0.0514.35%
2017-06-302017-08-08$45000-$0.04-$0.0514.35%
2017-03-312017-05-15$15000-$0.25-$0.04-614.29%
2016-12-312017-03-31$N/A-$0.03-$0.0862.5%
2016-09-302016-11-14$N/A-$0.11-$0.03-266.67%
2016-06-302016-08-15$N/A-$0.03
2016-03-312016-05-13$N/A-$0.04
2015-12-312016-03-30$135494-$0.03-$0.0650%
2015-09-302015-11-10$59000-$0.04
2015-06-302015-08-13$77000-$0.04
2015-03-312015-05-15$58000-$0.07
2014-12-312015-03-31$N/A-$0.09
2014-09-302014-11-14$N/A-$0.08
2014-06-302014-09-03$N/A-$0.08

Matinas BioPharma Holdings, Inc (MTNB) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Matinas BioPharma Holdings, Inc (MTNB) Chart:

Matinas BioPharma Holdings, Inc (MTNB) News:

Below you will find a list of latest news for Matinas BioPharma Holdings, Inc (MTNB) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Matinas BioPharma Holdings, Inc (MTNB) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest MTNB Trades:

Date Shares Price
Jun 13, 2022 7:39 PM EST2$0.77
Jun 13, 2022 7:40 PM EST100$0.7605
Jun 13, 2022 7:41 PM EST1$0.7605
Jun 13, 2022 7:45 PM EST5$0.7699
Jun 13, 2022 7:50 PM EST100$0.7615

Matinas BioPharma Holdings, Inc (MTNB) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220012586/0001493152-20-012586-index.htm
2020-07-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1582554/000000000020006525/0000000000-20-006525-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1582554/000119312520038357/0001193125-20-038357-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1582554/000121390020003599/0001213900-20-003599-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220000118/0001493152-20-000118-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220000120/0001493152-20-000120-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220000123/0001493152-20-000123-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220000124/0001493152-20-000124-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220000125/0001493152-20-000125-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220000126/0001493152-20-000126-index.htm
2020-01-09424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1582554/000149315220000415/0001493152-20-000415-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1582554/000149315220000458/0001493152-20-000458-index.htm
2020-01-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1582554/000149315220000492/0001493152-20-000492-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1582554/000149315220002757/0001493152-20-002757-index.htm
2020-03-0910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1582554/000149315220003558/0001493152-20-003558-index.htm
2020-03-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1582554/000149315220003603/0001493152-20-003603-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220004195/0001493152-20-004195-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220004196/0001493152-20-004196-index.htm
2020-03-20S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220004434/0001493152-20-004434-index.htm
2020-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220005693/0001493152-20-005693-index.htm
2020-04-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220006066/0001493152-20-006066-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1582554/000149315220008222/0001493152-20-008222-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1582554/000149315220008273/0001493152-20-008273-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220009089/0001493152-20-009089-index.htm
2020-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220009278/0001493152-20-009278-index.htm
2020-06-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1582554/000149315220010356/0001493152-20-010356-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220010651/0001493152-20-010651-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220011532/0001493152-20-011532-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220011533/0001493152-20-011533-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220011534/0001493152-20-011534-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220011535/0001493152-20-011535-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220011536/0001493152-20-011536-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220011758/0001493152-20-011758-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220011759/0001493152-20-011759-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220011760/0001493152-20-011760-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220011761/0001493152-20-011761-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220011762/0001493152-20-011762-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220011763/0001493152-20-011763-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220011764/0001493152-20-011764-index.htm
2020-07-02S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1582554/000149315220012535/0001493152-20-012535-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1582554/000149315220012547/0001493152-20-012547-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220012586/0001493152-20-012586-index.htm
2020-07-27S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1582554/000149315220014060/0001493152-20-014060-index.htm
2020-07-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1582554/000149315220014062/0001493152-20-014062-index.htm
2020-07-31CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1582554/000149315220014325/0001493152-20-014325-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1582554/000149315220015080/0001493152-20-015080-index.htm
2020-08-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1582554/000149315220015084/0001493152-20-015084-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1582554/000149315220015086/0001493152-20-015086-index.htm
2020-08-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220016580/0001493152-20-016580-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1582554/000149315220017845/0001493152-20-017845-index.htm
2020-09-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220017846/0001493152-20-017846-index.htm
2020-10-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1582554/000149315220019017/0001493152-20-019017-index.htm
2020-10-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1582554/000149315220019592/0001493152-20-019592-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1582554/000149315220020630/0001493152-20-020630-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1582554/000149315220020637/0001493152-20-020637-index.htm
2020-10-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1582554/000164117220000014/0001641172-20-000014-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1582554/000164117220000032/0001641172-20-000032-index.htm
2020-08-07EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1582554/999999999520002075/9999999995-20-002075-index.htm

Matinas BioPharma Holdings, Inc (MTNB) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Matinas BioPharma Holdings, Inc (MTNB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 771%
Institutional Ownership: 2363%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-06-30MATTHEW WIKLERDirectorBuy20,537.00211,905.00https://www.sec.gov/Archives/edgar/data/1582554/000149315220012586/0001493152-20-012586-index.htm
2020-09-30MATTHEW WIKLERDirectorBuy20,725.00232,630.00https://www.sec.gov/Archives/edgar/data/1582554/000149315220019017/0001493152-20-019017-index.htm
2020-08-21ADAM K STERNDirectorBuy20,000.000.8316,600.003,301,983.00https://www.sec.gov/Archives/edgar/data/1582554/000149315220016580/0001493152-20-016580-index.htm